Discovery calls best practices for 2026 for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install discovery calls has to reflect that reality from day one.

Best practices for discovery calls have shifted. The 2022 playbook does not survive the current buyer environment. This is the update.

Best practice one: fewer accounts, sharper triggers. Everything after discovery is downstream of what you learned in it, and generic coverage is now negative signal.

Best practice two: publish discovery-to-opportunity conversion weekly. If leadership does not see the number, the model quietly drifts.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Discovery calls is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Best practice three: separate the sending infrastructure from the primary brand. Deliverability is a strategic asset.

Best practice four: name a single owner. Committees produce compromise; owners produce numbers.

Best practice five: pre-write kill criteria. A stated failure threshold is what prevents the sunk-cost trap.

Best practice six: run monthly retrospectives that are honest about what did not work. Discovery calls improves faster on failure data than on success data.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing discovery calls properly rather than half-heartedly across three vendors.